By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on both CRISPR Therapeutics (CRSP) and Viking Therapeutics (VKTX) due to significant execution risks, reimbursement headwinds, intense competition, and financing cliffs.
Risk: Financing cliffs and potential dilution required to fund late-stage trials if companies stay independent.
Opportunity: Potential buyout opportunities for VKTX, but with no guarantee of fair value.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX), two mid-cap biotech companies that have lagged broader equities over the trailing-12-month period.
Even with these poor performances, however, there are solid reasons to consider investing in these stocks, especially at current levels. Read on to find out more.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
CRISPR Therapeutics made a breakthrough when it created Casgevy, the first gene-editing medicine that used the Nobel Prize-winning CRISPR technique to earn approval. The stock performed well from its 2016 initial public offering (IPO) until about 2021 but has been on a downward trajectory ever since for three reasons.
First, clinical progress is one of the most significant drivers of the performance of smaller biotech stocks. Once they start hitting major milestones, investors tend to take some profits.
Second, Casgevy is a gene-editing therapy that's complex to administer. Despite earning approval in late 2023, the therapy hasn't yet contributed much to CRISPR Therapeutics' results.
Third, the company is unprofitable. That's a big no-no in the current precarious market environment.
That said, CRISPR Therapeutics' next breakthrough could help the stock bounce back. The company is developing several promising medicines and expects data readouts for ongoing clinical trials as early as this year.
CRISPR Therapeutics is targeting challenging areas. The biotech is looking to develop medicines for type 1 diabetes, some hard-to-treat cancers, and other areas. Progress on these fronts could send the stock soaring.
Furthermore, Casgevy will ultimately have a significant impact on CRISPR Therapeutics' financial results. The company will share the profits from this medicine with giant drugmaker Vertex Pharmaceuticals, its collaborator in the development of this medicine, but CRISPR Therapeutics' partnership with Vertex was a net positive for the smaller biotech.
For one, CRISPR Therapeutics probably would not have earned approval for the treatment as quickly as it did in some places, including some countries in the Middle East, where the medicine boasts a more substantial commercial opportunity for Casgevy than the U.S. Securing approval and commercialization in the Middle East alone would have been far too expensive for a smaller drugmaker. Second, partly due to its long-standing partnership with Vertex, CRISPR Therapeutics has a substantial amount of liquidity, ending the first quarter with $1.86 billion in cash and equivalents.
Lastly, Casgevy has blockbuster potential. It costs $2.2 million per treatment course in the U.S., while the two partners estimate about 60,000 patients in their target geographies. Between Casgevy's long-term potential and the company's innovative pipeline, CRISPR Therapeutics could eventually recover and deliver exceptional returns to investors who stay the course.
Viking Therapeutics was a relatively unknown biotech until last year, when it produced strong phase 2 results for VK2735, an investigational weight management therapy. Although the stock soared following this data readout, it hasn't performed well since.
Nothing has gone wrong with Viking Therapeutics' leading candidate -- it's just another case of investors taking some profits. However, Viking Therapeutics looks attractive for several reasons.
The market for anti-obesity therapies is rapidly growing. There are scores of investigational therapies in this field, but most haven't delivered the kind of mid-stage data VK2735 has. The biotech company also has an oral formulation of VK2735 that's currently in Phase 2 studies.
Furthermore, Viking Therapeutics has several other candidates in development. The company's VK2809 is a potential treatment for metabolic dysfunction-associated steatohepatitis, which is also entering phase 3 studies after completing mid-stage trials.
Lastly, Viking's VK0214 is being developed for X-linked adrenoleukodystrophy, a rare genetic disorder affecting the nervous system. VK0214 has earned the orphan drug designation from the U.S. Food and Drug Administration, an honor reserved for medicines that have shown promising clinical data for the treatment of an orphan (or rare) disease with unmet needs.
Viking Therapeutics' pipeline is impressive for a biotech company worth just $3 billion. If it achieves clinical and regulatory successes in the coming years, its share price will likely skyrocket.
There is some risk involved here, as is always the case with clinical-stage biotechs. The stock could drop if it encounters setbacks, particularly with its leading candidate, VK2735. It's important to keep that in mind. But investors comfortable with the volatility should strongly consider initiating a small position in Viking Therapeutics.
Before you buy stock in CRISPR Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
*Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $697,627! **
Or when
Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $939,655!*Now, it’s worth noting Stock Advisor’s total average return is 1,045% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of June 30, 2025
Prosper Junior Bakiny has positions in Vertex Pharmaceuticals and Viking Therapeutics. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The commercialization hurdles for cell-based therapies and the intense competitive saturation in the obesity market make these 'dip' buys fundamentally speculative rather than value-based opportunities."
The article frames these as 'beaten-down' opportunities, but this is a classic trap in speculative biotech. For CRISPR Therapeutics (CRSP), the $1.86 billion cash position is a lifeline, but the commercial reality of Casgevy is brutal; gene-editing therapies face massive logistical hurdles in patient conditioning and reimbursement that the article glosses over. For Viking Therapeutics (VKTX), the valuation is entirely tethered to the GLP-1 weight-loss narrative. With Eli Lilly and Novo Nordisk dominating the supply chain and clinical infrastructure, VKTX is essentially a binary bet on being a buyout target rather than a standalone commercial success. Investors are essentially paying for high-risk clinical outcomes while ignoring the massive capital expenditure required to scale these specialized therapies.
If VKTX produces superior phase 2b data for its oral candidate, it becomes an immediate, high-premium acquisition target for a Big Pharma player desperate to diversify away from injectable-only weight loss portfolios.
"N/A"
[Unavailable]
"Both stocks are cheap for reasons—clinical-stage biotech execution risk and competitive saturation—that 'beaten down' framing obscures, and the article underestimates cash burn and reimbursement friction relative to upside optionality."
This article conflates 'beaten down' with 'undervalued'—a dangerous leap in biotech. CRSP trades at ~$90 with $1.86B cash but burns ~$400M annually; at that rate, runway is ~4.5 years even without revenue. Casgevy's $2.2M price tag faces reimbursement headwinds (only ~60k addressable patients globally is optimistic). VKTX's VK2735 data was strong, but the GLP-1 space is crowded with better-capitalized competitors (Novo, Eli Lilly, Viking itself has $1.2B market cap). Both stocks fell post-data because markets priced in execution risk, not profit-taking. The article ignores cash burn, competition intensity, and regulatory/reimbursement uncertainty.
If CRSP's pipeline delivers even one mid-stage win in diabetes or cancer, or if Casgevy adoption accelerates faster than expected, the risk/reward at current levels could genuinely favor longs; similarly, VKTX's oral formulation advantage in weight loss could be material if Phase 2 data holds.
"Near-term upside is precarious due to commercialization, pricing and clinical risk, and a misstep could wipe out gains."
While the article highlights Casgevy's potential and a robust cash cushion, the bear case is simple: biotechs with one approved therapy still carry execution risk that the market rarely prices out. For CRSP, Vertex collaboration cuts profits, and payer/reimbursement dynamics could cap US uptake; international opportunities remain uncertain and the addressable market estimates look optimistic. For VKTX, VK2735's Phase 2 success hasn't guaranteed late-stage efficacy or safety, and competition (GLP-1s and emerging oral therapies) could erode share. Financing risk looms if data disappoints; a few weak readouts could trigger meaningful multiple compression.
The downside risk exists, but catalysts matter: if readouts beat expectations and adoption accelerates, the upside could dwarf current fears; the article's gloom may be overly pessimistic.
"VKTX's current market valuation reflects a significant premium that ignores the high probability of equity dilution required to fund late-stage clinical trials."
Claude, your assessment of VKTX's market cap is outdated; it’s closer to $6-7 billion, not $1.2 billion, which fundamentally changes the acquisition math. While everyone is focused on commercial execution, you're all ignoring the 'platform' value. VKTX isn't just a GLP-1 play; it’s a portfolio of assets. If the oral candidate fails, the valuation floor collapses. The real risk isn't just competition—it's the massive dilution required to fund late-stage trials if they stay independent.
[Unavailable]
"VKTX's higher valuation actually amplifies dilution risk if late-stage data falters, not mitigates it."
Gemini's VKTX market-cap correction is fair, but it actually *strengthens* the dilution risk, not weakens it. A $6-7B valuation on ~$0 revenue means late-stage trials require massive capital raises at potentially compressed multiples if Phase 2b disappoints. The 'platform value' argument assumes successful execution across multiple assets—exactly what biotech investors overpay for. Nobody's flagged the financing cliff: if VK2735 Phase 2b shows safety concerns or efficacy gaps versus Novo/Lilly, VKTX faces a brutal capital raise or M&A at distressed terms.
"The platform-value thesis for VKTX is fragile; a Phase 2b miss or any setback can trigger expensive equity raises and lower the probability of a fair buyout price, so the 'big pharma acquirer' story may not materialize at current valuations."
Gemini, the platform-value angle is the most fragile part of VKTX's bull case. A single disappointing Phase 2b readout for VK2735 or a stumble in any other asset can unwind the diversified thesis, forcing costly capital raises or a distressed sale. Buyout optionality exists, but it is not a free lunch: dilution risk, financing cliffs, and potentially suppressed multiples mean the 'big pharma acquirer' bet may never materialize at fair value.
The panel consensus is bearish on both CRISPR Therapeutics (CRSP) and Viking Therapeutics (VKTX) due to significant execution risks, reimbursement headwinds, intense competition, and financing cliffs.
Potential buyout opportunities for VKTX, but with no guarantee of fair value.
Financing cliffs and potential dilution required to fund late-stage trials if companies stay independent.